Acer Therapeutics announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35M market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market. Accordingly, the listing matter is now closed and the previously-scheduled hearing before the Nasdaq Hearings Panel has been cancelled.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACER:
- Acer Therapeutics Compliant with All Nasdaq Listing Criteria
- Acer Therapeutics Plunges Despite FDA Win
- Acer Therapeutics, Relief announce FDA approval of Olpruva
- Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
- Acer Therapeutics receives FDA approval for NDA for Olpruva